Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death:: another vision of t(15;17) preleukemic blast and APL-cell maturation

被引:32
作者
Benoit, G [1 ]
Roussel, M [1 ]
Pendino, F [1 ]
Ségal-Bendirdjian, E [1 ]
Lanotte, M [1 ]
机构
[1] Hop St Louis, Ctr G Hayem, INSERM U 496, F-75010 Paris, France
关键词
APL; maturation; cell death; ATRA; cyclic AMP; 'rexinoids'; RXR signaling; cross-talk;
D O I
10.1038/sj.onc.1204760
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Despite intensive molecular biology investigations over the past 10 years, and an important breakthrough on how PML-RAR alpha, the fusion protein resulting from t(15;17), can alter RAR alpha and PML functions, no definitive views on how leukemia is generated and by what mechanism(s) the normal phenotype is restored, are yet available. 'Resistances' to pharmacological levels of all-traps-retinoic acid (ATRA) have been observed in experimental in vivo and in vitro models. In this review, we emphasize the key role played by signal cross-talk for both normal and neoplastic hemopoiesis. After an overview of reported experimental data on APL-cell maturation and apoptosis, we apply our current knowledge on signaling pathways to underline those which might generate signal cross-talks. The design of biological models suitable to decipher the integration of signal cross-talks at the transcriptional level should be our first priority today, to generate some realistic therapeutic approaches After 'Ten Years of Molecular APL', we still know very little about how the disease develops and how effective medicines work.
引用
收藏
页码:7161 / 7177
页数:17
相关论文
共 198 条
[51]  
Duprez E, 1996, ONCOGENE, V12, P2451
[52]  
DUPREZ E, 1992, LEUKEMIA, V6, P1281
[53]  
Edwards RH, 1999, AM J CLIN PATHOL, V112, P819
[54]  
El Marjou M, 2000, LEUKEMIA, V14, P2118
[55]   Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D-3 analogs and 9-cis retinoic acid [J].
Elstner, E ;
LinkerIsraeli, M ;
Le, J ;
Umiel, T ;
Michl, P ;
Said, JW ;
Binderup, L ;
Reed, JC ;
Koeffler, HP .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (02) :349-360
[56]  
Fenaux P, 1997, SEMIN ONCOL, V24, P92
[57]   Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia [J].
Fenaux, P ;
Chevret, S ;
Guerci, A ;
Fegueux, N ;
Dombret, H ;
Thomas, X ;
Sanz, M ;
Link, H ;
Maloisel, F ;
Gardin, C ;
Bordessoule, D ;
Stoppa, AM ;
Sadoun, A ;
Muus, P ;
Wandt, H ;
Mineur, P ;
Whittaker, JA ;
Fey, M ;
Daniel, MT ;
Castaigne, S ;
Degos, L .
LEUKEMIA, 2000, 14 (08) :1371-1377
[58]   All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia [J].
Fenaux, P ;
Chomienne, C ;
Degos, L .
SEMINARS IN HEMATOLOGY, 2001, 38 (01) :13-25
[59]   THE RNA COMPONENT OF HUMAN TELOMERASE [J].
FENG, JL ;
FUNK, WD ;
WANG, SS ;
WEINRICH, SL ;
AVILION, AA ;
CHIU, CP ;
ADAMS, RR ;
CHANG, E ;
ALLSOPP, RC ;
YU, JH ;
LE, SY ;
WEST, MD ;
HARLEY, CB ;
ANDREWS, WH ;
GREIDER, CW ;
VILLEPONTEAU, B .
SCIENCE, 1995, 269 (5228) :1236-1241
[60]   Growth advantage of chronic myeloid leukemia CFU-GM in vitro:: survival to growth factor deprivation, possibly related to autocrine stimulation, is a more common feature than hypersensitivity to GM-CSF/IL3 and is efficiently counteracted by retinoids ± α-interferon [J].
Ferrero, D ;
Foli, C ;
Giaretta, F ;
Argentino, C ;
Rus, C ;
Pileri, A .
LEUKEMIA, 2001, 15 (03) :422-429